Rights and permissions
About this article
Cite this article
Combination prostate cancer therapies too costly for payers. Pharmacoecon. Outcomes News 667, 15 (2012). https://doi.org/10.2165/00151234-201206670-00034
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206670-00034